Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Biotronik, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Biotronik, Inc.

Regulatory records
103
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 103 FDA records to the applicant name Biotronik, Inc.. The collection includes 1 510(k) clearance. It includes 5 original PMA approvals. 38 entries are PMA supplements. 59 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Oct 11, 1996 to Oct 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MRM appears in 36 of the 103 linked filings. The collection spans 8 FDA product codes and 5 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P950037, with 28 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 37 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 6024 Jean Rd., Lake Oswego, OR, 97035. Recorded on P950037/S300, decision dated Oct 28, 2026.

Changes described in PMA records

P950037/S300: Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,

FDA posted a 30-day notice for supplement S300 to PMA P950037, dated 2026-10-28, with decision OK30. The stated purpose is to implement updates to the final acceptance testing workflow for the Amvia/Solvia family of pacemakers and CRT-Ps. The supplement reason is recorded as a process change involving manufacturer, sterilizer, packager, or supplier.

The affected devices include Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edge DR-T, Amvia Edge SR-T, Solvia Rise DR-T, Solvia Rise SR-T, and Amvia Sky HF-T QP. The source statement does not describe the specific acceptance-testing changes, the manufacturing site, or any effect on device labeling or performance. A supplement of this type is not a new approval of the whole system.

FDA approval-order wording

to implement updates to the final acceptance testing workflow for the Amvia/Solvia family of pacemakers and CRT-Ps

Oct 28, 2026 · 30-Day Notice

P950037/S299: Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8

The FDA record for P950037/S299 describes a 30-day notice filed by Biotronik, Inc. under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The stated change is "updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing." In plain terms, incoming inspection for selected components and raw materials used in implantable pulse generator, implantable cardioverter defibrillator, and lead production is being revised on visual and dimensional criteria. The notice does not specify which components or raw materials, what the prior testing was, what replaces it, or the acceptance criteria.

The identifier ties this to PMA P950037, a supplement numbered S299, so the action amends the existing approval rather than constituting a new approval of the whole system. The device category is implantable pacemaker pulse-generator, product code DXY, cardiovascular specialty, with decision OK30 dated 2026-10-22. The stated purpose concerns inspection testing only; the record offers no independent evidence on safety, clinical effectiveness, or any change in indications, and it should not be read as such.

FDA approval-order wording

updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing

Oct 22, 2026 · 30-Day Notice

P070008/S184: Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR

This 30-day notice for PMA supplement P070008/S184 reports a change to incoming inspection procedures at Biotronik, Inc. The stated purpose is updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing. The affected device category is an implantable pulse generator with cardiac resynchronization (CRT-P), product code NKE.

The notice does not describe a new approval of the device system, a new indication, or clinical data. It is a process change involving manufacturer, sterilizer, packager, or supplier. The source statement does not specify which components or raw materials are affected, what dimensional tolerances changed, or how the updated testing relates to finished device performance.

FDA approval-order wording

updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing

Oct 22, 2026 · 30-Day Notice

P050023/S216: Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT

FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-22 for PMA supplement P050023/S216 from Biotronik, Inc. The supplement covers a process change attributed to manufacturer, sterilizer, packager or supplier activity, described as updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing. The listed products are Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, and Inlexa 7 VRT.

The device category is implantable dual-chamber defibrillator under product code MRM, specialty Cardiovascular. This action concerns incoming inspection of manufacturing inputs rather than a new approval of the whole system, and the record does not identify which components or raw materials are affected, what the prior inspection criteria were, or what evidence supported the change. The source lists no documents, so the filed notice itself was not reviewed.

Whether the revised inspection approach alters device performance or clinical use cannot be determined from the available fields, and no such conclusion is drawn here.

FDA approval-order wording

updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing

Oct 22, 2026 · 30-Day Notice

P000009/S135: Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur

FDA database entry P000009/S135 records a 30-Day Notice for Biotronik, Inc. The stated purpose is updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing. The listed device names include Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, and Rivacor Aur, under product code MRM for a dual-chamber implantable defibrillator.

The supplement reason is a process change involving manufacturer, sterilizer, packager, or supplier. The entry does not state which specific components or raw materials are affected, what dimensional or visual criteria changed, or whether any acceptance limits were revised. It also does not provide evidence of safety or clinical effectiveness. This supplement does not constitute a new approval of the original PMA system.

FDA approval-order wording

updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing

Oct 22, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik, Inc.PMA supplementOct 28, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA
BIOexpressP950037/S289
Biotronik, Inc.PMA supplementOct 16, 2026FDA
BIOexpressP070008/S177
Biotronik, Inc.PMA supplementOct 16, 2026FDA
BIOexpressP000009/S128
Biotronik, Inc.PMA supplementOct 16, 2026FDA
BIOexpressP050023/S209
Biotronik, Inc.PMA supplementOct 16, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 5, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 10, 2026FDA
Solia CSP SP950037/S297
Biotronik, Inc.PMA supplementAug 27, 2026FDA
Biotronik, Inc.PMA supplementJul 1, 2026FDA
Biotronik, Inc.PMA supplementJul 1, 2026FDA
Biotronik, Inc.PMA supplementJun 24, 2026FDA
Biotronik, Inc.PMA supplementJun 24, 2026FDA
Biotronik, Inc.PMA supplementJun 24, 2026FDA
Biotronik, Inc.PMA supplementMay 28, 2026FDA
Biotronik, Inc.PMA supplementMay 15, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.510(k) clearanceMay 1, 2026FDA
Renamic NeoP050023/S207
Biotronik, Inc.PMA supplementApr 24, 2026FDA
Renamic NeoP950037/S285
Biotronik, Inc.PMA supplementApr 24, 2026FDA
Renamic NeoP070008/S175
Biotronik, Inc.PMA supplementApr 24, 2026FDA
Renamic NeoP000009/S127
Biotronik, Inc.PMA supplementApr 24, 2026FDA
Solia CSP S LeadsP950037/S288
Biotronik, Inc.PMA supplementApr 2, 2026FDA
Biotronik, Inc.PMA supplementMar 30, 2026FDA
Biotronik, Inc.PMA supplementMar 27, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementFeb 12, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementDec 10, 2025FDA
Biotronik, Inc.PMA supplementDec 10, 2025FDA
Biotronik, Inc.PMA supplementOct 29, 2025FDA
Biotronik, Inc.PMA supplementOct 24, 2025FDA
Biotronik, Inc.PMA supplementOct 24, 2025FDA
Biotronik, Inc.PMA supplementOct 24, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementSep 11, 2025FDA
Biotronik, Inc.PMA supplementSep 11, 2025FDA
Biotronik, Inc.PMA supplementSep 11, 2025FDA
Biotronik, Inc.PMA supplementAug 22, 2025FDA
Biotronik, Inc.PMA approvalMay 12, 2008FDA
Biotronik, Inc.PMA approvalAug 10, 2006FDA
Biotronik, Inc.PMA approvalSep 29, 2000FDA
Biotronik, Inc.PMA approvalOct 27, 1998FDA
Biotronik, Inc.PMA approvalOct 11, 1996FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.